Drugs / INXN-4001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03409627 | Apr 2018 → Mar 2020 | heart failure | Triple-Gene, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INXN-4001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03409627 ↗ |
| Route | Other | “Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)” NCT03409627 ↗ |